TB Alliance Collaborates with Hongqi Pharma to Commercialize New Therapy for Highly Drug-Resistant Forms of TB in China

Shots:

• Hongqi to get a license to commercialize pretomanid as part of the three-drug “BPaL” regimen to treat a highly drug-resistant form of tuberculosis in People’s Republic of China
• The collaboration is a part of TB Alliance’s global commercialization strategy for pretomanid, complementing its previous agreement with Mylan & Macleods to commercialize pretomanid as part of the BPaL regimen in other countries
• Pretomanid is an anti-tuberculosis therapy & a part of BPaL (bedaquiline, pretomanid and linezolid) regimen, studied in P-III Nix-TB study and has received FDA’s approval as a combination therapy in Aug’2019

Click here ­to­ read full press release/ article | Ref: TB Alliance | Image: TB Alliance